Near‐Infrared Responsive PEGylated Gold Nanorod and Doxorubicin Loaded Dissolvable Hyaluronic Acid Microneedles for Human Epidermoid Cancer Therapy (Adv. Therap. 2/2018)

Human Epidermoid Cancer In article no. 1800008, ZhiYong Qian and co‐workers develop a near‐infrared (NIR) responsive PEGylated gold nanorod (GNR‐PEG) and doxorubicin (DOX) loaded dissolvable hyaluronic acid (HA) microneedle (GNR‐PEG&DOX@HA MN) for human epidermoid cancer therapy. The GNR‐PEG&...

Full description

Saved in:
Bibliographic Details
Published in:Advanced therapeutics 2018-06, Vol.1 (2), p.n/a
Main Authors: Hao, Ying, Chen, YuWen, Lei, MinYi, Zhang, TaoYe, Cao, YiPing, Peng, JinRong, Chen, LiJuan, Qian, ZhiYong
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human Epidermoid Cancer In article no. 1800008, ZhiYong Qian and co‐workers develop a near‐infrared (NIR) responsive PEGylated gold nanorod (GNR‐PEG) and doxorubicin (DOX) loaded dissolvable hyaluronic acid (HA) microneedle (GNR‐PEG&DOX@HA MN) for human epidermoid cancer therapy. The GNR‐PEG&DOX@HA MNs have good skin penetration capability and the release behavior of the DOX from GNR‐PEG&DOX@HA MNs can be controlled by near infra‐red light. An in vivo antitumor study, shows that transcutaneously delivered GNR‐PEG&DOX@HA MNs demonstrates remarkable antitumor efficacy, such that all treated mice were cured without recurrence after only one treatment.
ISSN:2366-3987
2366-3987
DOI:10.1002/adtp.201870004